Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress Presses FDA On Zohydro Approval As Product Launch Nears

This article was originally published in The Pink Sheet Daily

Executive Summary

Three Republican senators seek assurances about safeguards against, and monitoring for, abuse of Zogenix’s extended-release hydrocodone product, which is expected to reach commercial channels in early March.


Related Content

Abuse Reduction Claim In Opioid Label Will Be Difficult To Attain
Tighter REMS For Zohydro ER Still Insufficient For FDA Advisory Panel


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts